EP0031 Clinical Trials (2026): 1 Studies for Advanced Solid Tumor & NSCLC
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 EP0031 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced Solid Tumor & NSCLC) and 265 total planned enrollment. 1 EP0031 clinical trial is actively recruiting at 16 U.S. sites across 13 states. Most recent activity: NCT05443126 (Jun 2027).
Where to Participate: All EP0031 Trial Sites in the U.S. (16 sites across 13 states)
Every actively recruiting EP0031trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | David Geffen School of Medicine at UCLA | Los Angeles90095 | NCT05443126 | Map |
| CA | Stanford University | Stanford94305 | NCT05443126 | Map |
| DC | Georgetown University | Washington D.C.20057 | NCT05443126 | Map |
| FL | Florida Cancer Specialist | Fort Myers33908 | NCT05443126 | Map |
| IL | Northwestern University | Evanston60208 | NCT05443126 | Map |
| KY | University of Kentucky | Lexington40506 | NCT05443126 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05443126 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York07920 | NCT05443126 | Map |
| NY | NYU Langone Health | New York10016 | NCT05443126 | Map |
| OR | Providence Portland Medical Centre | Portland97213 | NCT05443126 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT05443126 | Map |
| TN | Sarah Cannon | Nashville37203 | NCT05443126 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT05443126 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT05443126 | Map |
| WA | Seattle Cancer Care / Fred Hutchinson Cancer Research Center | Seattle98109 | NCT05443126 | Map |
| WA | Washington University | Seattle63130 | NCT05443126 | Map |
EP0031 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting EP0031 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05443126 | A Study of EP0031 in Patients With Advanced RET-altered Malignancies | P1/P2 | Advanced Solid Tumor | 265 | Sep 2022 |
All EP0031 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05443126 | A Study of EP0031 in Patients With Advanced RET-altered Malignancies | P1/P2 | recruiting | 265 | Ellipses Pharma | Sep 2022 |
EP0031 clinical trials: frequently asked questions
- How many EP0031 clinical trials are there?
- 1 EP0031 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are EP0031 clinical trials recruiting in 2026?
- Yes — 1 EP0031 trial is actively recruiting in 2026, with 16 U.S. sites across 13 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is EP0031 being studied for?
- EP0031 is being studied for Advanced Solid Tumor, NSCLC. The trials are grouped by indication on this page.
- Who sponsors EP0031 clinical trials?
- The lead sponsor across the most EP0031 trials is Ellipses Pharma. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming EP0031as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: